Deepa Jagadeesh1, Steve Horwitz2, Nancy L Bartlett3, Youn Kim4, Eric Jacobsen5, Madeleine Duvic6, Meredith Little7, William Trepicchio7, Keenan Fenton8, Matthew Onsum8, Julie Lisano8, Ranjana Advani9. 1. Cleveland Clinic, Cleveland, OH, USA. 2. Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3. Washington University School of Medicine, Siteman Cancer Center, St. Louis, MO, USA. 4. Department of Dermatology, Stanford University School of Medicine, Stanford, CA, USA; Stanford Cancer Institute, Stanford, CA, USA. 5. Dana-Farber Cancer Institute, Boston, MA, USA. 6. The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 7. Millennium Pharmaceuticals, Inc., Cambridge, MA, USA (a wholly owned subsidiary of Takeda Pharmaceuticals Limited). 8. Seagen Inc., Bothell, WA, USA. 9. Stanford Cancer Institute, Stanford, CA, USA.
Abstract
BACKGROUND: The safety and efficacy of brentuximab vedotin (BV), an antibody-drug conjugate directed to the CD30 antigen, has been assessed in several trials in patients with peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL), or B-cell non-Hodgkin lymphoma (NHL). The objective of this research was to examine the relationship between CD30 expression level and clinical response to BV. PATIENTS AND METHODS: We analyzed response in patients treated with BV monotherapy in 5 prospective clinical studies in relapsed or refractory PTCL, CTCL, or B-cell NHL. CD30 expression was assessed by immunohistochemistry (IHC) using the Ber H2 antibody for 275 patients. RESULTS: Across all 5 studies, 140 (50.9%) patients had tumors with CD30 expression <10%, including 60 (21.8%) with undetectable CD30 by IHC. No significant differences were observed for any study in overall response rates between patients with CD30 expression ≥10% or <10%. Median duration of response was also similar in the CD30 ≥10% and <10% groups for all studies. CONCLUSIONS: In this analysis of studies across a range of CD30-expressing lymphomas, CD30 expression alone, as measured by standard IHC, does not predict clinical benefit from BV, making the determination of a threshold level of expression uncertain.
BACKGROUND: The safety and efficacy of brentuximab vedotin (BV), an antibody-drug conjugate directed to the CD30 antigen, has been assessed in several trials in patients with peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL), or B-cell non-Hodgkin lymphoma (NHL). The objective of this research was to examine the relationship between CD30 expression level and clinical response to BV. PATIENTS AND METHODS: We analyzed response in patients treated with BV monotherapy in 5 prospective clinical studies in relapsed or refractory PTCL, CTCL, or B-cell NHL. CD30 expression was assessed by immunohistochemistry (IHC) using the Ber H2 antibody for 275 patients. RESULTS: Across all 5 studies, 140 (50.9%) patients had tumors with CD30 expression <10%, including 60 (21.8%) with undetectable CD30 by IHC. No significant differences were observed for any study in overall response rates between patients with CD30 expression ≥10% or <10%. Median duration of response was also similar in the CD30 ≥10% and <10% groups for all studies. CONCLUSIONS: In this analysis of studies across a range of CD30-expressing lymphomas, CD30 expression alone, as measured by standard IHC, does not predict clinical benefit from BV, making the determination of a threshold level of expression uncertain.
Authors: Hinrich P Hansen; Andreas Recke; Ulrich Reineke; Bastian Von Tresckow; Peter Borchmann; Elke Pogge Von Strandmann; Hans Lange; Hilmar Lemke; Andreas Engert Journal: FASEB J Date: 2004-03-19 Impact factor: 5.191
Authors: Nancy L Bartlett; Mitchell R Smith; Tanya Siddiqi; Ranjana H Advani; Owen A O'Connor; Jeff P Sharman; Tatyana Feldman; Kerry J Savage; Andrei R Shustov; Catherine S Diefenbach; Yasuhiro Oki; Maria Corinna Palanca-Wessels; Mayur Uttarwar; Martha Li; Jing Yang; Eric D Jacobsen Journal: Leuk Lymphoma Date: 2016-11-20
Authors: G Pizzolo; F Vinante; M Chilosi; F Dallenbach; O Josimovic-Alasevic; T Diamantstein; H Stein Journal: Br J Haematol Date: 1990-06 Impact factor: 6.998
Authors: Youn H Kim; Mahkam Tavallaee; Uma Sundram; Katrin A Salva; Gary S Wood; Shufeng Li; Sima Rozati; Seema Nagpal; Michael Krathen; Sunil Reddy; Richard T Hoppe; Annie Nguyen-Lin; Wen-Kai Weng; Randall Armstrong; Melissa Pulitzer; Ranjana H Advani; Steven M Horwitz Journal: J Clin Oncol Date: 2015-07-20 Impact factor: 44.544
Authors: Steven M Horwitz; Ranjana H Advani; Nancy L Bartlett; Eric D Jacobsen; Jeff P Sharman; Owen A O'Connor; Tanya Siddiqi; Dana A Kennedy; Yasuhiro Oki Journal: Blood Date: 2014-03-20 Impact factor: 22.113
Authors: Alex F Herrera; Alison J Moskowitz; Nancy L Bartlett; Julie M Vose; Radhakrishnan Ramchandren; Tatyana A Feldman; Ann S LaCasce; Stephen M Ansell; Craig H Moskowitz; Keenan Fenton; Carol Anne Ogden; David Taft; Qu Zhang; Kazunobu Kato; Mary Campbell; Ranjana H Advani Journal: Blood Date: 2017-12-11 Impact factor: 25.476